 Anastacia Garcia
Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Caenorhabditis elegans | 4 | 2016 | 306 | 0.860 |
Why?
| | Superoxide Dismutase | 3 | 2024 | 346 | 0.830 |
Why?
| | Myocytes, Cardiac | 4 | 2021 | 526 | 0.800 |
Why?
| | Ventricular Remodeling | 3 | 2021 | 266 | 0.790 |
Why?
| | Heart Ventricles | 5 | 2020 | 788 | 0.760 |
Why?
| | Hypoxia | 4 | 2024 | 1112 | 0.670 |
Why?
| | Cardiolipins | 1 | 2020 | 85 | 0.630 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2018 | 22 | 0.590 |
Why?
| | Heart Failure | 4 | 2020 | 2236 | 0.560 |
Why?
| | Heart Defects, Congenital | 3 | 2020 | 842 | 0.520 |
Why?
| | Ventricular Function, Right | 1 | 2018 | 285 | 0.490 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2024 | 2189 | 0.490 |
Why?
| | Glucose | 2 | 2016 | 1020 | 0.410 |
Why?
| | Microscopy, Video | 1 | 2012 | 25 | 0.400 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2015 | 319 | 0.390 |
Why?
| | Lipid Metabolism | 2 | 2016 | 518 | 0.380 |
Why?
| | Mitochondria, Heart | 2 | 2025 | 102 | 0.380 |
Why?
| | Microscopy, Confocal | 1 | 2012 | 325 | 0.360 |
Why?
| | Inflammation | 2 | 2020 | 2837 | 0.340 |
Why?
| | Transcriptome | 4 | 2021 | 971 | 0.320 |
Why?
| | Bleomycin | 2 | 2020 | 248 | 0.280 |
Why?
| | Cardiomyopathy, Dilated | 2 | 2021 | 385 | 0.270 |
Why?
| | Calcium | 3 | 2022 | 1199 | 0.260 |
Why?
| | Myocardial Contraction | 2 | 2025 | 341 | 0.240 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1774 | 0.240 |
Why?
| | Ceramides | 2 | 2016 | 118 | 0.230 |
Why?
| | Signal Transduction | 2 | 2016 | 5079 | 0.230 |
Why?
| | Sphingosine | 1 | 2025 | 46 | 0.230 |
Why?
| | Lysophospholipids | 1 | 2025 | 80 | 0.220 |
Why?
| | Insulin | 1 | 2015 | 2409 | 0.220 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2025 | 135 | 0.220 |
Why?
| | Perfusion | 1 | 2025 | 213 | 0.210 |
Why?
| | Mitochondrial Membrane Transport Proteins | 1 | 2022 | 43 | 0.200 |
Why?
| | Focal Adhesions | 1 | 2021 | 44 | 0.180 |
Why?
| | Cation Transport Proteins | 1 | 2022 | 134 | 0.180 |
Why?
| | Calcium-Binding Proteins | 1 | 2022 | 218 | 0.180 |
Why?
| | Extracellular Matrix | 2 | 2024 | 528 | 0.180 |
Why?
| | Animals | 11 | 2025 | 36940 | 0.170 |
Why?
| | Calcium Channel Agonists | 1 | 2020 | 12 | 0.170 |
Why?
| | Probenecid | 1 | 2020 | 8 | 0.170 |
Why?
| | Blalock-Taussig Procedure | 1 | 2020 | 5 | 0.170 |
Why?
| | Heart Bypass, Right | 1 | 2020 | 17 | 0.160 |
Why?
| | Patient-Specific Modeling | 1 | 2020 | 41 | 0.160 |
Why?
| | Animals, Newborn | 2 | 2021 | 844 | 0.160 |
Why?
| | Troponin I | 1 | 2019 | 81 | 0.150 |
Why?
| | DNA, Mitochondrial | 1 | 2020 | 200 | 0.150 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2018 | 37 | 0.150 |
Why?
| | Heart Transplantation | 1 | 2025 | 754 | 0.150 |
Why?
| | Fontan Procedure | 1 | 2020 | 180 | 0.140 |
Why?
| | Acute Lung Injury | 1 | 2020 | 287 | 0.130 |
Why?
| | Cardiomyopathies | 1 | 2020 | 350 | 0.130 |
Why?
| | Mice, Inbred C57BL | 3 | 2025 | 5757 | 0.120 |
Why?
| | Up-Regulation | 1 | 2018 | 843 | 0.120 |
Why?
| | Down-Regulation | 1 | 2017 | 657 | 0.120 |
Why?
| | Carbohydrate Metabolism | 1 | 2015 | 59 | 0.120 |
Why?
| | Inheritance Patterns | 1 | 2014 | 45 | 0.110 |
Why?
| | Cells, Cultured | 2 | 2019 | 4193 | 0.110 |
Why?
| | MicroRNAs | 1 | 2020 | 692 | 0.100 |
Why?
| | Chromatin Assembly and Disassembly | 1 | 2014 | 104 | 0.100 |
Why?
| | Male | 10 | 2025 | 67762 | 0.100 |
Why?
| | Child, Preschool | 4 | 2021 | 11074 | 0.100 |
Why?
| | Rats, Sprague-Dawley | 1 | 2018 | 2486 | 0.100 |
Why?
| | Models, Animal | 1 | 2014 | 384 | 0.100 |
Why?
| | Myocardium | 1 | 2017 | 1002 | 0.100 |
Why?
| | RNA, Messenger | 1 | 2020 | 2833 | 0.090 |
Why?
| | Animals, Genetically Modified | 1 | 2012 | 240 | 0.090 |
Why?
| | Fatty Acids | 1 | 2015 | 443 | 0.090 |
Why?
| | Oxygen | 1 | 2016 | 931 | 0.090 |
Why?
| | Child | 6 | 2021 | 21935 | 0.090 |
Why?
| | Stress, Physiological | 1 | 2014 | 443 | 0.090 |
Why?
| | Case-Control Studies | 1 | 2018 | 3556 | 0.090 |
Why?
| | Microbial Collagenase | 1 | 2010 | 12 | 0.080 |
Why?
| | Fibrillar Collagens | 1 | 2010 | 13 | 0.080 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3284 | 0.080 |
Why?
| | Humans | 11 | 2024 | 137585 | 0.080 |
Why?
| | Lung | 2 | 2024 | 4060 | 0.080 |
Why?
| | Epigenesis, Genetic | 1 | 2014 | 660 | 0.080 |
Why?
| | Gene Expression Regulation | 1 | 2018 | 2607 | 0.080 |
Why?
| | Keratinocytes | 1 | 2010 | 249 | 0.070 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2012 | 752 | 0.070 |
Why?
| | Female | 6 | 2021 | 73304 | 0.070 |
Why?
| | Diet | 1 | 2015 | 1278 | 0.070 |
Why?
| | Mice | 4 | 2025 | 17787 | 0.060 |
Why?
| | Cell Movement | 1 | 2010 | 967 | 0.060 |
Why?
| | Fibroblasts | 1 | 2010 | 996 | 0.060 |
Why?
| | Cellular Reprogramming | 1 | 2024 | 99 | 0.050 |
Why?
| | Aging | 1 | 2014 | 1864 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2010 | 2475 | 0.050 |
Why?
| | Disulfides | 1 | 2022 | 107 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2025 | 4295 | 0.050 |
Why?
| | Endopeptidase K | 1 | 2021 | 17 | 0.050 |
Why?
| | Ribonucleases | 1 | 2021 | 55 | 0.050 |
Why?
| | Calcium Channels | 1 | 2022 | 159 | 0.050 |
Why?
| | Macrophages, Alveolar | 1 | 2024 | 391 | 0.040 |
Why?
| | Microscopy, Atomic Force | 1 | 2021 | 126 | 0.040 |
Why?
| | Triggering Receptor Expressed on Myeloid Cells-1 | 1 | 2020 | 7 | 0.040 |
Why?
| | RAW 264.7 Cells | 1 | 2020 | 50 | 0.040 |
Why?
| | TRPV Cation Channels | 1 | 2020 | 40 | 0.040 |
Why?
| | Adenosine Triphosphate | 1 | 2022 | 491 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 622 | 0.040 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2020 | 127 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2021 | 455 | 0.040 |
Why?
| | Administration, Oral | 1 | 2020 | 816 | 0.040 |
Why?
| | Exercise Test | 1 | 2020 | 625 | 0.030 |
Why?
| | Mutation | 2 | 2020 | 3958 | 0.030 |
Why?
| | Metabolic Detoxication, Phase II | 1 | 2016 | 3 | 0.030 |
Why?
| | Metabolic Detoxication, Phase I | 1 | 2016 | 6 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2017 | 346 | 0.030 |
Why?
| | Xenobiotics | 1 | 2016 | 32 | 0.030 |
Why?
| | Genetic Markers | 1 | 2017 | 344 | 0.030 |
Why?
| | Macrophages | 1 | 2024 | 1547 | 0.030 |
Why?
| | Homeostasis | 1 | 2020 | 621 | 0.030 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2017 | 121 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2016 | 327 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2019 | 771 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2016 | 499 | 0.030 |
Why?
| | Phosphorylation | 1 | 2019 | 1759 | 0.030 |
Why?
| | Genotype | 1 | 2020 | 1916 | 0.030 |
Why?
| | Fibrosis | 1 | 2017 | 552 | 0.030 |
Why?
| | Caenorhabditis elegans Proteins | 1 | 2016 | 199 | 0.030 |
Why?
| | Nuclear Envelope | 1 | 2014 | 40 | 0.030 |
Why?
| | Hypertension, Pulmonary | 1 | 2024 | 1910 | 0.020 |
Why?
| | Rats | 1 | 2021 | 5647 | 0.020 |
Why?
| | Computational Biology | 1 | 2016 | 644 | 0.020 |
Why?
| | Adolescent | 2 | 2021 | 21513 | 0.020 |
Why?
| | Cell Migration Assays | 1 | 2010 | 3 | 0.020 |
Why?
| | Clostridium | 1 | 2010 | 17 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2010 | 1092 | 0.020 |
Why?
| | Prospective Studies | 1 | 2020 | 7604 | 0.020 |
Why?
| | Phenotype | 1 | 2016 | 3196 | 0.020 |
Why?
| | Adult | 2 | 2020 | 37929 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2017 | 6079 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2020 | 10811 | 0.020 |
Why?
| | Young Adult | 1 | 2020 | 13209 | 0.010 |
Why?
| | Infant | 1 | 2017 | 9465 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2020 | 15657 | 0.010 |
Why?
|
|
Garcia's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|